Metabolic Disorders

Hepion shelves Phase II NASH trial amid shallow cash resources

Hepion Pharmaceuticals has called it quits on a Phase IIb trial investigating the biotech’s lead drug candidate for the treatment…

TheracosBio’s BRENZAVVY meets primary endpoint in type 2 diabetes trial

TheracosBio has reported data from a Phase III clinical trial where BRENZAVVY (bexagliflozin) as an adjunct to metformin in managing…

Diamyd Medical reaches recruitment milestone in Phase III T1D trial

Diamyd Medical has reported that its Phase III DIAGNODE-3 clinical trial of antigen-specific immunotherapy, Diamyd, in Type 1 Diabetes (T1D)…

Lipocine hopes obesity drug could boost muscle mass in combo with GLP1-RAs

Lipocine hopes its obesity candidate LPCN 2401 could work alongside glucagon-like peptide-1 receptor agonists (GLP1-RAs) to help improve muscle mass…

Eli Lilly begins Phase III trials of oral weight loss drug in India 

Eli Lilly has reportedly commenced Phase III clinical trials of oral medication, orforglipron, for weight loss in India.   The oral…

89bio wins EMA priority status for MASH candidate pegozafermin

The European Medicine’s Agency (EMA) has granted priority medicines (PRIME) status to 89bio’s pegozafermin, a drug being evaluated to treat…

Viking reports positive data from Phase I oral obesity treatment trial

Viking Therapeutics has reported positive data from its Phase I multiple ascending dose (MAD) clinical trial of VK2735, an oral…

Hua Medicine plans to focus T2D drug on diabetic kidney disease patients

China-based Hua Medicine plans to focus on the US trial development of its type 2 diabetes (T2D) drug in diabetic…

Pipeline moves: Approval prospects for SBS candidate rise after Phase III trial meets endpoints

This week on Pipeline Moves, we kick off by looking at success of a Phase III trial of Ironwood Pharmaceuticals’…

Empros Pharma to dose patients in Phase III obesity trial before end of year

Swedish biopharma Empros Pharma will dose the first subjects with its obesity combination therapy in a Phase III trial before…

close

Sign up to the newsletter: In Brief

Your corporate email address *
First name *
Last name *
Company name *
Job title *
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close